Labetalol

Wallin, J. D.; OʼNeill, William M.

doi:10.1001/archinte.1983.00350030099017

Arch Intern Med

1983

DOI: 10.1001/archinte.1983.00350030099017

|View full text |Cite

Labetalol

J. D. Wallin¹,

William M. OʼNeill²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1985

1999

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 35 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Labetalol has been developed as an oral and intravenous agent. It has been used for the treatment of patients with essential hypertension, hypertensive emergencies, and hypertension associated with pheochromocytoma and pregnancy, as well as for angina pectoris, which is the focus of this symposium [3][4][5]. Labetalol has also been used as a hypotensive agent during general anesthesia [3].…”

mentioning

confidence: 99%

Properties of labetalol, a combined ?-and ?-blocking agent, relevant to the treatment of myocardial ischemia

Frishman

1988

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Labetalol, a combined alpha-beta-adrenergic antagonist, is one of the new group of beta-adrenergic blockers reduces peripheral and coronary vascular resistances while preserving cardiac output. Unlike alpha-adrenergic blockers, labetalol tends to reduce heart rate during rest and exercise. The drug is a potent antihypertensive agent which has been used by mouth and by vein to treat mild, moderate, and severe hypertension, including hypertensive emergencies. Labetalol has a hemodynamic profile which makes it an attractive agent for treating myocardial ischemia. The drug reduces blood pressure, left ventricular wall tension, heart rate, and contractility while preserving or even augmenting coronary blood flow. Studies with labetalol in hypertensive patients with angina have shown it to be more effective than placebo in reducing angina attacks and blood pressure while improving exercise tolerance. The drug appears to have antianginal and antihypertensive effects comparable to atenolol and propranolol. Side effects of treatment are observed and most are related to alpha- and beta-adrenergic blockade. Labetalol also appears to be effective for treatment of normotensive patients with angina and for silent myocardial ischemia. It has no apparent effects on serum lipids and lipoproteins. Labetalol appears to be a useful drug for treating the hypertensive heart and its many complications.

show abstract

mentioning

confidence: 99%

Properties of labetalol, a combined ?-and ?-blocking agent, relevant to the treatment of myocardial ischemia

Frishman

1988

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

“…47:77-89, 1999. © 1999 INTRODUCTION β-Adrenoceptor blockers, such as pindolol, celiprolol, bucindolol, labetalol, and carvedilol, have ancillary vasodilatory properties [Abrahamsson, 1986;Frishman, 1991;Hershberger et al, 1990;Wallin and O'Neill, 1983;Sponer et al, 1987]. Of these, carvedilol has been accepted for use in the treatment of patients with chronic heart failure [Eichhon, 1992;Bristow, 1993].…”

mentioning

confidence: 99%

Ferulidilol: A vasodilatory and antioxidant adrenoceptor and calcium entry blocker, with ancillary ?2-agonist activity

Huang

Yeh

et al. 1999

Drug Dev. Res.

View full text Add to dashboard Cite

Treatment of Hypertensive Emergencies and Urgencies With Oral Clonidine Loading and Titration

Houston¹

1986

Arch Intern Med

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Labetalol

Cited by 35 publications

References 47 publications

Properties of labetalol, a combined ?-and ?-blocking agent, relevant to the treatment of myocardial ischemia

Properties of labetalol, a combined ?-and ?-blocking agent, relevant to the treatment of myocardial ischemia

Ferulidilol: A vasodilatory and antioxidant adrenoceptor and calcium entry blocker, with ancillary ?2-agonist activity

Treatment of Hypertensive Emergencies and Urgencies With Oral Clonidine Loading and Titration

Contact Info

Product

Resources

About